Recent Reports


2011-11-14: Biotechnology and Pharmaceuticals Report
5 leading Analysts; and top management from 4 Sector Firms examine this industry.
Order this Report
More Information

2011-10-31: Health Care IT Report
4 leading Analysts; and top management from 5 Sector Firms examine this industry.
Order this Report
More Information

2011-10-17: Medical Research, Diagnostic Substances & Life Science Tools Report
4 leading Analysts; and top management from 3 Sector Firms examine this industry.
Order this Report
More Information

2011-10-03: Medical Real Estate Report
3 leading Analysts; and top management from 3 Sector Firms examine industry.
Order this Report
More Information

2011-07-11: Medical Devices Report
5 leading Analysts; and top management from 12 Sector Firms examine this industry.
Order this Report
More Information

2011-06-27: Health Care IT Report
6 leading Analysts; and top management from 9 Sector Firms examine this industry.
Order this Report
More Information

2011-06-13: Medical Research, Diagnostic Substances & Life Science Tools Report
5 leading Analysts; and top management from 3 Sector Firm examine this industry.
Order this Report
More Information

2011-04-04: Biotechnology and Pharmaceuticals Report
3 leading Analysts; and top management from 5 Sector Firms examine this industry.
Order this Report
More Information

2011-01-24: Medical Devices Report
3 leading Analysts; and top management from 9 Sector Firms examine this industry.
Order this Report
More Information

Search TWST Online

TWST Newsletter

Give us your email address and receive the TWST Newsletter.


Company Interview Excerpt
Cleveland BioLabs, Inc. - Dr. Michael Fonstein


Full article published: 01/25/2010


For Subscribers

Get this article online now!

Order just this article
TWST: You have two families of drugs, correct? One is Curaxins, anti-cancer drugs that don't use chemotherapy?
Dr. Fonstein: Yes.

TWST: The others are Protectans, which are designed to keep healthy cells protected from radiation and chemotherapy. It's that family of drugs that can be used by the government in the event of a radiation attack, right?
Dr. Fonstein: Yes, that is what we are developing as a defense antidote, yes.

TWST: What therapies are currently available in these areas besides yours? How will your drugs improve on them?
Dr. Fonstein: In radiation, there are no similar drugs to deal with acute radiation syndrome (ARS). There are basically drugs like iodide, which substitutes for radioactive iodide in your thyroid gland; it's important for children who got radiation damage through contamination of their bodies. But if you are, let's say, hit by an electromagnetic pulse or by a radiation pulse, iodide is no more helpful than table salt. So there is really nothing there except us.

 

Tickers included in this excerpt: CBLI

 

For more information call (212) 952 7433. The Wall Street Transcript does not endorse any of the comments made by interviewees, and does not make stock recommendations.